Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Emergency Physicians Urged Not to Prescribe New Opioid, Zohydro ER, Given High Potential for Abuse

By Frank LoVecchio, DO, MPH, FACEP | on June 10, 2014 | 1 Comment
Features
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version
Zohydro ER

Patients and physicians want better pain relief and improved patient satisfaction. Mandates warrant “significant decreases in pain scores,” further increasing the demand for a drug such as Zohydro ER. Logically, drug companies will increase supply based on demand. Regulations, lobbying, restrictions, and patient and physician education may decrease the demand for opioids. As individuals, and hopefully as a group, the simplest way for us to decrease demand for Zohydro ER and similar products is not to prescribe them. In conclusion, until further data are available—especially addressing post-marketing safety—it is best to “say no to Zohydo” in the ED.

You Might Also Like
  • Congress Questions Ethics Behind FDA Approval of Zohydro ER
  • Critics of Zohydro ER Approval Suspect Conflict of Interest with Pharmaceutical Industry
  • FDA Panel Backs Teva’s Abuse-Resistant Opioid Painkiller
Explore This Issue
ACEP Now: Vol 33 – No 06 – June 2014

Dr. LoVecchio is vice chair and research director at the Maricopa Medical Center in Phoenix, professor of emergency medicine, pharmacology, and medicine at the University of Arizona College of Medicine in Tucson, and co–medical director of the Banner Good Samaritan Poison & Drug Information Center.

References

  1. Rauck RL, Nalamachu S, Wild JE, et al. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study. Pain Med. 2014 Feb 12. [Epub ahead of print]
  2. Zohydro ER package insert. Zogenix Web site. Available at: www.zogenix.com/pdf/ZohydroER_PI_FINAL_102513.pdf. Accessed May 12, 2014.
  3. Ramin CJ. Why did the F.D.A. approve a new pain drug? The New Yorker. Dec. 3, 2013. Available at: http://www.newyorker.com/online/blogs/currency/2013/12/zohydro-why-did-the-fda-approve-a-new-pain-drug.html. Accessed May 12, 2014.
  4. Associated Press. Abuse-resistant hydrocodone could sink sales of new drug. New York Times. March 12, 2014. Available at: www.nytimes.com/2014/03/13/business/abuse-resistant-hydrocodone-could-sink-sales-of-new-drug.html?src=recg&_r=0. Accessed May 12, 2014.

Pages: 1 2 3 | Single Page

Topics: AddictionDrug AbuseDrug ApprovalDrug SafetyEmergency DepartmentEmergency MedicineEmergency PhysicianFDAOpioidOpioid CrisisPainPatient SafetyPharmaceutical IndustryPrescriptionZohydro ER

Related

  • Q&A with ACEP President L. Anthony Cirillo

    November 5, 2025 - 0 Comment
  • Overcoming Language Barriers in the Emergency Department

    October 21, 2025 - 0 Comment
  • Event Medicine: Where Fun and Safety Sing in Perfect Harmony

    October 9, 2025 - 1 Comment

Current Issue

ACEP Now: November 2025

Download PDF

Read More

One Response to “Emergency Physicians Urged Not to Prescribe New Opioid, Zohydro ER, Given High Potential for Abuse”

  1. March 27, 2019

    David Reply

    Doctors need to be aware of a patient’s true need for an Opioid drug. They need more training to determine a patient’s potential for abuse.

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*


Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603